Table 2. Description of study treatment received by patients along the study.

Variable	Bortezomib		Lenalidomide (N=162)
	Standard dose (N=31)	Low dose (N=57)
Treatment duration, months
Mean (s.d.)	3.8 (1.4)	4.1 (2.1)	5.0 (3.3)
Median (Q1–Q3)	3.7 (2.4–5.1)	4.7 (2.4–5.6)	5.5 (3.0–6.3)
Min–max	1.5–6.9	0.2–10.9	0.4–29.5
Cumulative dosage, mg/m2 or mg
Mean (s.d.)	25.8 (8.7)	10.8 (8.8)	2019.4 (1271.1)
Median (Q1–Q3)	24.9 (19.5–31.2)	7.8 (5.2–10.4)	1945.0 (835.0–3175.0)
Min–max	10.5–44.1	2.3–41.6	100.0–4950.0
Average dosage, mg/m2 or mg per cycle
Mean (s.d.)	4.7 (0.7)	3.6 (1.7)	14.7 (6.6)
Median (Q1–Q3)	5.1 (4.2–5.2)	2.7 (2.5–4.8)	15.0 (10.0–19.1)
Min–max	2.9–5.8	1.6–7.5	2.8–25.0